Upadacitinib Reduces Non-Nociceptive Pain in axSpA
Upadacitinib treatment was associated with reduced non-nociceptive pain among patients with axSpA, including both neuropathic and nociplastic types.
Treatment with upadacitinib improves non-nociceptive pain among patients with axial spondyloarthritis (axSpA), with reductions found for both neuropathic and nociplastic pain scores, according to study results presented at the American College of Rheumatology (ACR) Convergence 2025.
The oral Janus kinase inhibitor upadacitinib has previously shown benefit for reducing inflammation and nociceptive pain in axSpA. However, patients may also experience non-nociceptive pain — including nociplastic and neuropathic pain — which can contribute to ongoing symptoms such as sleep disturbances, anxiety, and depression.
Author's summary: Upadacitinib reduces non-nociceptive pain in axSpA patients.
More News
- 5 principles for our once-in-a-generation reset on inclusion
- “TAIYO YUDEN Leading the Way In Miniature Electronics”
- NHS launches AI trial to diagnose prostate cancer up to a month faster
- ‘Like It Was Yesterday’: The 1985 Villanova Football Team Reunited For Its 40th Anniversary
- £160bn in surplus assets: Discover how Mercer is helping unlock it
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks
- Liquid assets: November 2025
- Gmail Data Breach: 183 million accounts exposed in massive leak
- When Bill Skarsgård's Pennywise Appears in It TV Show Possibly Revealed - Comic Book Movies and Superhero Movie News - SuperHeroHype